New vaccine aims to stop stomach bug norovirus
NCT ID NCT06630117
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new vaccine called V330 to see if it is safe and how well it triggers an immune response against norovirus, a virus that causes vomiting and diarrhea. The trial included 245 healthy adults aged 18-49 and 60-79. Participants received either the vaccine or a placebo, and researchers monitored side effects and antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
V330 vaccine
What this could lead to
If successful, this could lead to a safe vaccine that protects against norovirus, a common cause of severe stomach illness.
What could go wrong
This is an early Phase 1 trial focused on safety, not yet proving the vaccine works. It is small and results may not apply to larger populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Clinical Trials Medical Group managed by PAREXEL ( Site 0002)
Glendale, California, 91206, United States
-
QPS-MRA, LLC-Early Phase ( Site 0006)
South Miami, Florida, 33143, United States
-
Research Centers of America ( Hollywood ) ( Site 0004)
Hollywood, Florida, 33024, United States
-
Velocity Clinical Research, Hallandale Beach ( Site 0003)
Hallandale, Florida, 33009, United States